Reaction
Phaeohyphomycosis reporting signals
As of the last recalculation, Phaeohyphomycosis appears in 453 FAERS reports alongside 16 co-occurring drug terms. The strongest observed disproportionality signal is TACROLIMUS OINTMENT 0.1% (PRR 543.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Tacrolimus Ointment 0.1% | 347 | 543.9 | 545.4 |
| Tacrolimus Extended-Release Capsules | 347 | 542.4 | 543.9 |
| Tacrolimus | 351 | 453.8 | 454.9 |
| Mycophenolate Mofetil | 245 | 179.3 | 179.7 |
| Mycophenolate Mofetil Hydrochloride | 245 | 179.0 | 179.3 |
| Itraconazole | 37 | 158.4 | 158.9 |
| Posaconazole Delayed-Release | 29 | 129.6 | 129.9 |
| Mycophenilic Acid | 44 | 107.9 | 108.2 |
| Voriconazole Injection | 43 | 100.4 | 100.6 |
| Posaconazole | 29 | 87.5 | 87.7 |
| Voriconazole | 43 | 71.8 | 71.9 |
| Mycophenolic Acid | 44 | 69.9 | 69.9 |
| Terbinafine Hydrochloride | 7 | 36.8 | 36.8 |
| Basiliximab | 9 | 35.9 | 35.9 |
| Valganciclovir Hydrochloride Powder, | 9 | 34.6 | 34.6 |
| Tofacitinib Citrate | 8 | 28.5 | 28.5 |